PCH
ITCI

Polar Capital Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Polar Capital Holdings’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-928,745
Closed -$66.5M – 312
2023
Q4 		$66.5M Sell
928,745
-71,255
-7% -$4.1M 0.41% 70
2023
Q3 		$52.1M Buy
1,000,000
+600,000
+150% +$35M 0.39% 76
2023
Q2 		$25.3M Hold
400,000
– – 0.13% 129
2023
Q1 		$21.7M Sell
400,000
-48,580
-11% -$2.35M 0.14% 133
2022
Q4 		$23.7M Sell
448,580
-155,670
-26% -$7.8M 0.19% 133
2022
Q3 		$28.1K Sell
604,250
-284,287
-32% -$14.9M 0.18% 114
2022
Q2 		$50.7K Buy
888,537
+367,094
+70% +$20.8M 0.3% 77
2022
Q1 		$31.9K Buy
521,443
+429,708
+468% +$22.3M 0.14% 128
2021
Q4 		$4.8K Hold
91,735
– – 0.02% 261
2021
Q3 		$3.42K Buy
91,735
+33,291
+57% +$1.16M 0.01% 293
2021
Q2 		$2.39K Buy
+58,444
New +$2.16M 0.01% 300
2021
Q1 		– Sell
-10,558
Closed -$336K – 358
2020
Q4 		$336K Buy
+10,558
New +$277K ﹤0.01% 314

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polar Capital Holdings's ITCI Position: Q1 2024 in Review

Polar Capital Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 928,745 shares — an estimated $66.5M sold.

Polar Capital Holdings first reported a position in ITCI in Q4 2020 and held it in 12 quarters. The position peaked at $66.5M in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Polar Capital Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Polar Capital Holdings sold 928,745 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $66.5M.
  • Polar Capital Holdings first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 12 quarters.
  • Polar Capital Holdings's Intra-Cellular Therapies Inc. position peaked at $66.5M in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Polar Capital Holdings's 13F filing for Q1 2024, filed 15 May 2024.